Net profit attributable to mother exceeded the upper limit of the pre-expectation by 30%! YIDU TECH (02158) reversed losses into profits in the 2026 fiscal year, and operating cash flow turned positive.

On June 30, the leading domestic AI medical company YIDU TECH (02158) released its annual performance for the year ending March 31, 2026. The financial report was impressive, as the company achieved annual profitability for the first time. It reported an annual profit of RMB 78.766 million, exceeding the previous profit expectation range of RMB 55-70 million, with a net profit to shareholders of RMB 72.709 million, also significantly surpassing the estimated range of RMB 41-56 million, with an excess of up to 30%. Revenue increased by approximately 14.6% year-on-year to RMB 820 million, and the net cash flow from operating activities in the second half of the reporting period turned positive, reaching RMB 29.3 million. The overall gross profit margin further improved to 36.4% compared to the same period last year, demonstrating an upward trend in profitability. The performance announcement showed that all three main business sectors maintained steady growth, creating a strong performance base. The core business segment, AI for Medical (big data platform and solutions), generated revenue exceeding RMB 3.8 billion for the fiscal year, a 10.2% year-on-year increase. This business has served 133 top domestic hospitals and 54 regulatory agencies, with a network covering over 12,000 hospitals. During the reporting period, it successfully bid for projects such as the Hainan infectious disease monitoring platform and the smart health island, as well as deepening cooperation with renowned tertiary hospitals such as the Beijing Cancer Hospital and Peking University First Hospital. The increase in operational efficiency in this sector boosted the gross profit margin significantly from 29.7% in the previous fiscal year to 39.7% in the reporting period. The AI for Life Sciences sector generated revenue exceeding RMB 2.7 billion, a 9.4% year-on-year increase. The business continued to focus on pharmaceutical services throughout the entire lifecycle, participating in or completing over 516 clinical research projects, including those initiated by drug companies and researchers. Additionally, more than 320 prospective and retrospective real-world research projects were conducted, with 17 of the top 20 multinational pharmaceutical companies being clients of YIDU TECH. The AI for Care sector had revenue of approximately RMB 1.7 billion, a significant increase of 37.6% year-on-year, leading in growth rate among the three sectors. The company has been the main operator of the Shenzhen HUIMINBAO and Beijing PUHUI healthcare platforms for four and five consecutive years, respectively, covering a large number of insured individuals. The intelligent fast-tracked claims model has greatly improved claims efficiency. Furthermore, the digital diabetes therapy has been implemented in 105 core medical institutions in five cities and counties such as Sanya, Qionghai, Wanning, and Lingshui, extending to more regions such as Shanxi province and Tianjin city. With all three tracks advancing in unison, YIDU TECH has laid a solid foundation for long-term development.